Patents by Inventor Neil Hunter
Neil Hunter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20040072242Abstract: The present invention relates generally to a method for detecting, enumerating and/or identifying microorganisms in a sample. More particularly, the present invention provides a method for determining total microbial content in a sample by detecting the presence of nucleotide sequences associated with all or part of 16S rDNA or its corresponding 16S rRNA or its homologue, functional equivalent or derivative. The nucleotide sequences of the present invention may be used as an indicator of any microorganism and, hence, represents a universal target sequence which is indicative of total microbial content in a sample. The universal target sequence may also be varied to render same genus or species specific or the universal target used to trap microbial DNA or RNA which may be subsequently analyzed by sequence analysis or genetic probe technology.Type: ApplicationFiled: September 17, 2003Publication date: April 15, 2004Inventors: Neil Hunter, Nicholas A. Jacques, Fjelda E. Martin, Mangala A. Nadkarni
-
Publication number: 20030069430Abstract: Compounds of formula (I): wherein X is N, CH, CCF3, or C(C1-12 aliphatic); R4 is sulfonic acid, C1-12 aliphatic-sulfonyl, sulfonyl-C1-12 aliphatic, C1-12 aliphatic-sulfonyl-C1-6 aliphatic, C1-6 aliphatic-amino, R7-sulfonyl, R7 sulfonyl-C1-12 aliphatic, R7-aminosulfonyl, R7aminosulfonyl-C1-12 aliphatic, R7-sulfonylamino, R7-sulfonylamino-C1-12 aliphatic, aminosulfonylamino, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-C1-12 aliphatic aminosulfonyl, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-C1-12 aliphatic aminosulfonyl-C1-12 aliphatic, (R8)1-3-Arylamino, (R8)1-3-Arylsulfonyl, (R8)1-3-Aryl-aminosulfonyl, (R8)1-3-Aryl-sulfonylamino, Het-amino, Het-sulfonyl, Het-aminosulfonyl, aminoiminoamino, or aminoiminoaminosulfonyl, R5 is hydrogen; and further wherein R4 and R5 are optionally joined to form a fused ring, pharmaceutical formulations comprising them and their use in therapy, especially in the treatment of diseases mediated by CDK2 activity, such as alopecia induced by canType: ApplicationFiled: November 30, 2001Publication date: April 10, 2003Inventors: Stephen Thomas Davis, Scott Howard Dickerson, Stephen Vernon Frye, Philip Anthony Harris, Robert Neil Hunter, Lee Frederick Kuyper, Karen Elizabeth Lackey, Michael Joseph Luzzio, James Marvin Veal, Duncan Herrick Walker
-
Patent number: 6541503Abstract: Compounds of formula (I): wherein X is N, CH, CCF3, or C(C1-12 aliphatic); R4 is sulfonic acid, C1-12 aliphatic-sulfonyl, sulfonyl-C1-12 aliphatic, C1-12 aliphatic-sulfonyl-C1-6 aliphatic, C1-6 aliphatic-amino, R7-sulfonyl, R7 sulfonyl-C1-12 aliphatic, R7-aminosulfonyl, R7-aminosulfonyl-C1-12 aliphatic, R7-sulfonylamino, R7-sulfonylamino-C1-12 aliphatic, aminosulfonylamino, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-C1-12 aliphatic aminosulfonyl, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-C1-12 aliphatic aminosulfonyl-C1-12 aliphatic, (R8)1-3-Arylamino, (R8)1-3-Arylsulfonyl, (R8)1-3-Aryl-aminosulfonyl, (R8)1-3-Aryl-sulfonylamino, Het-amino, Het-sulfonyl, Het-aminosulfonyl, aminoiminoamino, or aminoiminoaminosulfonyl, R5 is hydrogen; and further wherein R4 and R5 are optionally joined to form a fused ring, pharmaceutical formulations comprising them and their use in therapy, especially in the treatment of diseases mediated by CDK2 activity, such as alopecia induced by caType: GrantFiled: August 8, 2001Date of Patent: April 1, 2003Assignee: SmithKline Beecham CorporationInventors: Stephen Thomas Davis, Scott Howard Dickerson, Stephen Vernon Frye, Philip Anthony Harris, Robert Neil Hunter, III, Lee Frederick Kuyper, Karen Elizabeth Lackey, Michael Joseph Luzzio, James Marvin Veal, Duncan Herrick Walker
-
Publication number: 20030004351Abstract: Compounds of formula (I): wherein X is N, CH, CCF3, or C(C1-12 aliphatic); R4 is sulfonic acid, C1-12 aliphatic-sulfonyl, sulfonyl-C1-12 aliphatic, C1-12 aliphatic-sulfonyl-C1-6 aliphatic, C1-6 aliphatic-amino, R7-sulfonyl, R7 sulfonyl-C1-12 aliphatic, R7-aminosulfonyl, R7-aminosulfonyl-C1-12 aliphatic, R7-sulfonylamino, R7-sulfonylamino-C1-12 aliphatic, aminosulfonylamino, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-Cl1-12 aliphatic aminosulfonyl, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-C1-12 aliphatic aminosulfonyl-C1-12 aliphatic, (R8)1-3-Arylamino, (R8)1-3-Arylsulfonyl, (R8)1-3-Aryl-aminosulfonyl, (R8)1-3-Aryl-sulfonylamino, Het-amino, Het-sulfonyl, Het-aminosulfonyl, aminoiminoamino, or aminoiminoaminosulfonyl, R5 is hydmogen; and further wherein R4 and R5 are optionally joined to form a fused ring, pharmaceutical formulations comprising them and their use in therapy, especially in the treatment of diseases mediated by CDK2 activity, such as alopecia induced by cType: ApplicationFiled: August 8, 2001Publication date: January 2, 2003Inventors: Stephen Thomas Davis, Scott Howard Dickerson, Stephen Vernon Frye, Philip Anthony Harris, Robert Neil Hunter, Lee Frederick Kuyper, Karen Elizabeth Lackey, Michael Joseph Luzzio, James Marvin Veal, Duncan Herrick Walker
-
Patent number: 6387919Abstract: Compounds of formula (I): wherein X is N, CH, CCF3, or C(C1-12 aliphatic); R4 is sulfonic acid, C1-12 aliphatic-sulfonyl, sulfonyl-C1-12 aliphatic, C1-12 aliphatic-sulfonyl-C1-6 aliphatic, C1-6 aliphatic-amino, R7-sulfonyl, R7 sulfonyl-C1-12 aliphatic, R7-aminosulfonyl, R7-aminosulfonyl-C1-12 aliphatic, R7-sulfonylamino, R7-sulfonylamino-C1-12 aliphatic, aminosulfonylamino, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-C1-12 aliphatic aminosulfonyl, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-C1-12 aliphatic aminosulfonyl-C1-12 aliphatic, (R8)1-3-Arylamino, (R8)1-3-Arylsulfonyl, (R8)1-3-Aryl-aminosulfonyl, (R8)1-3-Aryl-sulfonylamino, Het-amino, Het-sulfonyl, Het-aminosulfonyl, aminoiminoamino, or aminoiminoaminosulfonyl, R5 is hydrogen; and further wherein R4 and R5 are optionally joined to form a fused ring, pharmaceutical formulations comprising them and their use in therapy, especially in the treatment of diseases mediated by CDK2 activity, such as alopecia induced by caType: GrantFiled: June 6, 2000Date of Patent: May 14, 2002Assignee: Glaxo Wellcome Inc.Inventors: Stephen Thomas Davis, Scott Howard Dickerson, Philip Anthony Harris, Robert Neil Hunter, III, Lee Frederick Kuyper, Michael Joseph Luzzio, James Marvin Veal, Duncan Herrick Walker
-
Patent number: 6369086Abstract: The present invention relates generally to novel substituted oxindole compounds and compositions. Such compounds and compositions have utility as pharmacological agents in treating diseases or conditions alleviated by the inhibition or antagonism of protein kinase activated signalling pathways. In particular, the present invention relates to a series of substituted oxindole compounds, which exhibit protein tyrosine kinase and protein serine/threonine kinase inhibition, and which are useful in inhibiting tumor growth via inhibition of such kinases as well as protecting a patient undergoing chemotherapy from chemotherapy induced alopecia.Type: GrantFiled: March 4, 1999Date of Patent: April 9, 2002Assignee: SmithKline Beecham CorporationInventors: Stephen Thomas Davis, Scott Howard Dickerson, Philip Anthony Harris, Robert Neil Hunter, III, Lee Frederick Kuyper, Karen Elizabeth Lackey, Michael Joseph Luzzio, James Marvin Veal, Duncan Herrick Walker
-
Patent number: 6268391Abstract: Compounds of general formula (I) wherein: R1 is H or optionally joined with R2 to form a fused ring selected from the group consisting of five to ten membered aryl, heteroaryl or heterocyclyl rings, R2 and R3 are independently H, HET, aryl, C1-12 aliphatic, CN, NO2, halogen, R10, —OR10, —SR10, —S(O)R10, —SO2R10, —NR10R11, —NR11R12, —NR12COR11, —NR12CO2R11, —NR12CONR11R12, —NO12SO2R11, —NR12C(NR 12)NHR11, —COR11, —CO2R11, —CONR12R11, —SO2NR12R11, —OCONR12R11, C(NR12)NR12R11, R6 and R7 are independently halogen, CN, NO2, —CONR10R11, —SO2NR10R11, —NR10R11, or —OR11, where R10 and R11 are as defined below; R8 is OH, NHSO2R12 or NHCOCF3; and their use in therapy, especially in the treatment of disorders mediated by cRaf1 kinase.Type: GrantFiled: April 7, 2000Date of Patent: July 31, 2001Assignee: Glaxo Wellcome Inc.Inventors: Scott Howard Dickerson, Philip Anthony Harris, Robert Neil Hunter, III, David Kendall Jung, Karen Elizabeth Lackey, Robert Walton McNutt, Jr., Michael Robert Peel, James Marvin Veal
-
Patent number: 6131874Abstract: An information display system in which positional incompatibility with respect to a user of a display screen is overcome by means of making the screen pivotable to align with the user. Pivotal adjustment can be manual, or (in some embodiments) automatically performed by an in-built user-sensing camera. To protect the display system from children, the display is rendered inactive if the user's height is sensed as being below a pre-set minimum height.Type: GrantFiled: March 15, 1999Date of Patent: October 17, 2000Assignee: IMS Innovation LimitedInventors: Gordon Vance, Neil Hunter
-
Patent number: 4046540Abstract: The production of shaped glass articles is undertaken by an injection moulding process by charging a particulate inorganic glass having a transformation temperature of not greater than 300.degree. C to an injection moulding machine; by converting the glass to a molten state in the barrel of the machine; and by injecting the molten glass into a mould on the machine.Type: GrantFiled: June 16, 1975Date of Patent: September 6, 1977Assignee: Imperial Chemical Industries LimitedInventors: Cyril John Lewis, Neil Carter, Neil Hunter Ray
-
Patent number: 3989532Abstract: An optical article, for example, a lens, window or mirror, at least part of the surface of which, and preferably the whole of which, is an inorganic oxide glass having a P.sub.2 O.sub.5 content of at least 52 mole %, and preferably 55 to 68.5 mole %, an alkaline earth content of 2.7 to 20 mole %, and a transformation temperature of not greater than 300.degree. C, the glass optionally containing B.sub.2 O.sub.3 and at least one alkali metal oxide.Type: GrantFiled: February 4, 1974Date of Patent: November 2, 1976Assignee: Imperial Chemical Industries LimitedInventors: Neil Hunter Ray, William Derek Robinson, Cyril John Lewis
-
Patent number: 3964919Abstract: Phosphate glasses containing minor amounts of the oxides of chromium, molybdenum and tungsten (Group VIb) have improved water resistance and low softening points. Suitable compositions are within the range (moles percent)P.sub.2 o.sub.5 50-75Group VIb oxides 0.1-10, comprising singly or in combination CrO.sub.3 up to 2.6, MoO.sub.3 up to 7, WO.sub.3 up to 7At least one oxide selected from alkali metal oxides and alkaline earths 15- 49.9Addition of oxidizing agents (e.g. sodium nitrate) to the melt may be used to keep the Group VIb metals in the hexavalent state.Type: GrantFiled: July 29, 1975Date of Patent: June 22, 1976Assignee: Imperial Chemical Industries LimitedInventors: Neil Hunter Ray, William Derek Robinson, Cyril John Lewis
-
Patent number: 3935018Abstract: Inorganic oxide glasses having compositions within the range (in moles percent) B.sub.2 O.sub.3 1.2-3.5, P.sub.2 O.sub.5 50-72, PbO 0-30, transition metal oxides 0-5, the remainder being oxides selected from alkali metal oxides, alkaline earths and zinc oxide.Type: GrantFiled: April 12, 1973Date of Patent: January 27, 1976Assignee: Imperial Chemical Industries LimitedInventors: Neil Hunter Ray, William Derek Robinson
-
Patent number: 3933689Abstract: The addition of a low softening point glass of Tg 300.degree.C and optionally a blowing agent, to a reinforced thermosetting composite material gives fire retardant properties to the product. Smoke emission on burning is less than for halogenated fire retardant additives. A preferred embodiment is GRP sheet containing a powdered phosphate glass and a blowing agent.Type: GrantFiled: May 23, 1973Date of Patent: January 20, 1976Assignee: Imperial Chemical Industries LimitedInventors: Neil Hunter Ray, Bryan Shaw, Bruce Cochran Lane
-
Patent number: 3931064Abstract: An isocyanate-based polymeric foam material having dispersed therein a particulate low-softening point inorganic oxide glass having a transformation temperature of not greater than 300.degree.C, and optionally a blowing agent which is capable of liberating a non-flammable gas on heating above a temperature in the range 150.degree. to 400.degree.C.Type: GrantFiled: May 6, 1974Date of Patent: January 6, 1976Assignee: Imperial Chemical Industries LimitedInventors: Neil Hunter Ray, Bruce Cochran Lane, Bryan Shaw